Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bloch

Showing results (461-470 of 471) with videos related to

Pageof 48
Sort By:
JAMA Cardiology|November 9, 2022
Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical TrialMichel Azizi, Felix Mahfoud, Michael A Weber, et al.
The Oncologist|July 25, 2015
Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical CenterLaura J Tafe, Ivan P Gorlov, Francine B de Abreu, et al.
Journal of Human Hypertension|May 25, 2021
Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO studyManish Saxena, Roland E Schmieder, Ajay J Kirtane, et al.
JACC. Advances|February 17, 2026
Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and DesignJorge Plutzky, Pam R Taub, Deepak L Bhatt, et al.
Circulation|October 26, 2023
Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial ProgramMichel Azizi, Andrew S P Sharp, Naomi D L Fisher, et al.
Lancet (London, England)|May 28, 2018
Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trialMichel Azizi, Roland E Schmieder, Felix Mahfoud, et al.
JAMA|February 28, 2023
Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical TrialMichel Azizi, Manish Saxena, Yale Wang, et al.
JAMA Cardiology|February 28, 2023
Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO TrialsAjay J Kirtane, Andrew S P Sharp, Felix Mahfoud, et al.
JACC. Cardiovascular Interventions|December 28, 2020
12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal DenervationMichel Azizi, Joost Daemen, Melvin D Lobo, et al.
Lancet (London, England)|May 19, 2021
Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trialMichel Azizi, Kintur Sanghvi, Manish Saxena, et al.
Pageof 48

Showing results (461-470 of 471) with videos related to

Sort By:
Pageof 48
JAMA Cardiology|November 9, 2022
Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical TrialMichel Azizi, Felix Mahfoud, Michael A Weber, et al.
The Oncologist|July 25, 2015
Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical CenterLaura J Tafe, Ivan P Gorlov, Francine B de Abreu, et al.
Journal of Human Hypertension|May 25, 2021
Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO studyManish Saxena, Roland E Schmieder, Ajay J Kirtane, et al.
JACC. Advances|February 17, 2026
Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and DesignJorge Plutzky, Pam R Taub, Deepak L Bhatt, et al.
Circulation|October 26, 2023
Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial ProgramMichel Azizi, Andrew S P Sharp, Naomi D L Fisher, et al.
Lancet (London, England)|May 28, 2018
Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trialMichel Azizi, Roland E Schmieder, Felix Mahfoud, et al.
JAMA|February 28, 2023
Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical TrialMichel Azizi, Manish Saxena, Yale Wang, et al.
JAMA Cardiology|February 28, 2023
Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO TrialsAjay J Kirtane, Andrew S P Sharp, Felix Mahfoud, et al.
JACC. Cardiovascular Interventions|December 28, 2020
12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal DenervationMichel Azizi, Joost Daemen, Melvin D Lobo, et al.
Lancet (London, England)|May 19, 2021
Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trialMichel Azizi, Kintur Sanghvi, Manish Saxena, et al.
Pageof 48